HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drescher, P. Articles by Crain, M. R. Search for Related Content PubMed PubMed Citation Articles by Drescher, P. Articles by Crain, M. R. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Catheter-Directed Thrombolytic Therapy in Peripheral Artery Occlusions: Combining Reteplase and Abciximab

¹ Department of Radiology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226.
² Great Lakes Radiologists, 2560 Norman Ct., Brookfield, WI 53045.
³ Department of Radiologists, Our Lady of Lourdes Medical Center, 1600 Haddon Ave., Camden, NJ 08103.

OBJECTIVE. The goal of this study was to assess the safety and efficacy of combination therapy consisting of the third-generation plasminogen activator reteplase and the glycoproteins IIb and IIIa platelet receptor antagonist abciximab for thrombolysis in peripheral artery occlusive disease. This two-center experience focused on immediate thrombolytic success, thrombolysis time, complication rate, and 30-day patency rate.

SUBJECTS AND METHODS. Fifty patients with arterial occlusive disease (age range, 40–96 years; mean age, 69 years) were prospectively enrolled at two centers. Eighteen patients (36%) had native artery thromboses, and 32 patients (64%) had graft thromboses. Catheter-directed intraarterial thrombolytic infusion of reteplase (average dose, 0.51 U/hr; range, 0.25–1 U/hr) was combined with IV infusion of abciximab (bolus, 0.25 mg/kg of body weight; 12-hr infusion, 0.125 µg/kg of body weight per minute). Nontherapeutic heparin (100–400 U/hr) was given intraarterially during the thrombolytic infusion.

RESULTS. Complete thrombolysis was achieved in 89% of the patients with native artery occlusions and 94% of the patients with graft occlusions for an overall rate of 92%. The average thrombolysis time was 20.7 hr (range, 4–41 hr) with a mean reteplase dose of 12.1 U (range, 2–23 U). Major hematoma occurred in 12% of the patients, with an average blood transfusion of 3.1 U of packed RBC (range, 1–11 U), and correlated to increased thrombolysis time and dose. No intracranial hemorrhage occurred. The 30-day primary patency rate was 92%. Two patients (4%) underwent amputation, including one major amputation (2%), within 30 days of thrombolysis.

CONCLUSION. The combination of reteplase and abciximab in catheter-directed arterial thrombolysis is feasible and effective. Results of this combination therapy suggest acceptable thrombolysis times and doses with tolerable complication rates. Which patient group might benefit the most from combination therapy and the long-term results of combination therapy still need to be determined.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Tepe, C. Hopfenzitz, K. Dietz, J. Wiskirchen, S. Heller, K. Ouriel, G. Ziemer, C. D. Claussen, and S. H. Duda Peripheral Arteries: Treatment with Antibodies of Platelet Receptors and Reteplase for Thrombolysis--APART Trial Radiology, June 1, 2006; 239(3): 892 - 900. [Abstract] [Full Text] [PDF]